For instance, while biologic therapy can achieve clinical remission, a study of severe asthma in adult patients reported remission in less than a quarter of the cases15; and in pediatric patients with elevated BEC and IgE, treatment with the IL-4 receptor antagonist Dupilumab only halves the risk of exacerbations compared to a placebo over a year2, suggesting that its efficacy may be limited in certain subgroups of the targeted population. This evidence concerns the gene IGHE and asthma.